Prevagen and Neuriva are over-the-counter brain health supplements marketed to improve memory and focus, but neither has strong independent scientific support for its claims. Prevagen relies on an ingredient (apoaequorin) that breaks down almost completely during digestion, leaving minimal intact protein to reach the brain, while Neuriva has published one manufacturer-funded study showing modest short-term improvements in a small group.
Both companies faced legal consequences for overstating their products' benefits. Prevagen settled an FTC lawsuit in 2020 for deceptive advertising claims about memory and Alzheimer's benefits, and Neuriva's manufacturer settled an $8 million class action suit for falsely claiming the product was "clinically proven" without adequate support. If you're considering either supplement, the verified research shows you should expect minimal benefit and understand the limits of what these companies have actually demonstrated.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Prevagen's Ingredient Actually Works in Your Body
- Neuriva's Study Results and What They Actually Mean
- Why Both Companies Settled with Regulators
- The Core Difference in Evidence Quality
- What to Do If You're Considering Brain Health Support
- Frequently Asked Questions
How Prevagen's Ingredient Actually Works in Your Body
Prevagen's active ingredient is apoaequorin, a protein originally sourced from jellyfish. When you swallow it, your digestive system treats it like any other protein: over 90% breaks down into amino acids within 30 seconds of exposure to pepsin, the enzyme in your stomach.
This means the intact protein never reaches your bloodstream or brain in meaningful amounts. The company's marketing rests on the idea that apoaequorin can bind calcium in brain cells and improve signaling, but that mechanism only matters if the protein survives digestion—which the research shows it does not. Without independent peer review of Prevagen's clinical evidence, the three studies the company cites lack proper blinding, placebo controls, and dose transparency, and two were never published in peer-reviewed journals at all.
Neuriva's Study Results and What They Actually Mean
Neuriva has one double-blind, placebo-controlled study in adults aged 40–65 that ran for 42 days. The results look promising on the surface: the study reported 24% memory improvement and 30.5% focus improvement versus placebo, but critical details limit how much you should trust these findings.
First, the study included only 138 people and lasted six weeks—too short to show whether cognitive benefits hold over months or years. Second, the study was funded by Neuriva's manufacturer, not independent researchers, which raises the risk of bias in design or reporting. Third, Neuriva's formula contains 100 mg of phosphatidylserine daily, one-third the 300 mg dose used in clinical trials showing cognitive benefits, so it's unclear whether Neuriva delivers an equivalent effect.
Why Both Companies Settled with Regulators
Prevagen's 2020 FTC settlement addressed years of marketing claims that the product improved memory and Alzheimer's risk without adequate evidence to back them up. The company paid a settlement related to these charges but did not admit wrongdoing, and the core product remains on shelves with largely unchanged marketing.
Neuriva faced a separate legal challenge: the company claimed its product was "clinically proven" and "scientifically proven" based on limited evidence. Between January 2019 and April 2021, purchasers sued, and Neuriva's manufacturer settled the class action for $8 million, compensating customers for the misleading language. Like Prevagen, Neuriva continues to be sold, but the settlement signals that regulators and courts viewed the original marketing claims as unsupported.
The Core Difference in Evidence Quality
The most important difference between these two products is not which is better, but how much evidence either has. Neither product shows strong independent peer-reviewed evidence—Prevagen lacks adequate clinical support entirely, while Neuriva has one small manufacturer-funded study.
This matters because a manufacturer-funded study in a small group over a short timeframe is a lower bar than independent verification, and Prevagen clears even that low bar. Neuriva's primary ingredient, coffee cherry extract, does raise levels of a brain growth factor called BDNF in some studies, but sustained cognitive benefits from this mechanism remain unproven in long-term human trials. If Neuriva showed a real effect in its one study, it was modest and temporary; no independent researcher has replicated it.
What to Do If You're Considering Brain Health Support
If you're worried about memory or focus, neither Prevagen nor Neuriva has demonstrated clear benefits strong enough to justify their cost or reliance. Evidence for cognitive decline prevention points instead to modifiable lifestyle factors: regular aerobic exercise, cognitive engagement (reading, puzzles, learning), sleep, stress management, and a Mediterranean-style diet rich in fish and plants.
If you've already tried either supplement and feel you benefit from it, the research suggests any improvement is likely placebo effect or coincidental improvement from lifestyle changes—but that does not mean stopping it will harm you. If you're taking one because a doctor or pharmacist recommended it, ask them what independent evidence supports their recommendation, as the research record is thin.
Frequently Asked Questions
Can apoaequorin in Prevagen actually reach my brain?
No. Over 90% of apoaequorin breaks down into amino acids in your stomach within 30 seconds, leaving almost none intact to be absorbed or circulate to the brain.
Does Neuriva's study prove the supplement works?
The study shows a short-term effect in one small group, but it was funded and designed by Neuriva's manufacturer, lasted only 42 days, and no independent researcher has confirmed the results. That's far short of proof.
Why did both companies get sued?
Prevagen settled an FTC lawsuit for false advertising claims about memory and Alzheimer's benefits, and Neuriva settled an $8 million class action for claiming to be "clinically proven" without adequate evidence.
